TitleEditing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies.
Publication TypeJournal Article
Year of Publication2023
AuthorsVenkatesan V, Christopher ACrystal, Rhiel M, Azhagiri MKumar K, Babu P, Walavalkar K, Saravanan B, Andrieux G, Rangaraj S, Srinivasan S, Karuppusamy KV, Jacob A, Bagchi A, Pai AAnand, Nakamura Y, Kurita R, Balasubramanian P, Pai R, Marepally SKumar, Mohankumar KMurugesan, Velayudhan SR, Boerries M, Notani D, Cathomen T, Srivastava A, Thangavel S
JournalMol Ther Nucleic Acids
Date Published2023 Jun 13

Reactivation of fetal hemoglobin (HbF) is a commonly adapted strategy to ameliorate β-hemoglobinopathies. However, the continued production of defective adult hemoglobin (HbA) limits HbF tetramer production affecting the therapeutic benefits. Here, we evaluated deletional hereditary persistence of fetal hemoglobin (HPFH) mutations and identified an 11-kb sequence, encompassing putative repressor region (PRR) to β-globin exon-1 (βE1), as the core deletion that ablates HbA and exhibits superior HbF production compared with HPFH or other well-established targets. PRR-βE1-edited hematopoietic stem and progenitor cells (HSPCs) retained their genome integrity and their engraftment potential to repopulate for long-term hematopoiesis in immunocompromised mice producing HbF positive cells . Furthermore, PRR-βE1 gene editing is feasible without HSPC culture. Importantly, the editing induced therapeutically significant levels of HbF to reverse the phenotypes of both sickle cell disease and β-thalassemia major. These findings imply that PRR-βE1 gene editing of patient HSPCs could lead to improved therapeutic outcomes for β-hemoglobinopathy gene therapy.

Alternate JournalMol Ther Nucleic Acids
PubMed ID37215154
PubMed Central IDPMC10197010